Gilead Sciences is a biopharmaceutical company that discovers, develops and commercialises innovative therapeutics in areas of unmet medical need. With headquarters in Foster City, California, Gilead has operations in North America, Europe and Australia. Gilead maintains research, development or manufacturing facilities in the US and Europe and employs more than 1,600 people worldwide.

A Scientific Approach
Gilead uses the most advanced scientific tools to develop therapeutics for the treatment of infectious diseases. By examining key viral enzymes required for the replication of pathogenic viruses in host cells, Gilead scientists aim to design and synthesise new antiviral drugs with enhanced potency, an improved resistance profile, prolonged duration of activity and better selectivity.

Expanding Leadership in Viral Hepatitis
Gilead markets Hepsera^® (adefovir dipivoxil) for chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alanine aminotransferase (ALT) or aspartate aminotransferase (AST)) or histologically active disease. Gilead is committed to increasing and improving the treatment options for hepatitis B and C, which affect more than 500 million people worldwide, and has recently laid the groundwork for an expanded hepatitis portfolio.

Two Phase III clinical trials of tenofovir disoproxil fumarate, which is currently marketed as Viread^® for the treatment of HIV, recently began enrollment among patients with chronic hepatitis B. Through partnerships and in-house research programmes, Gilead is also investigating various small molecule inhibitors of the hepatitis C virus.

Advanced Care
In addition to developing medicines that improve the treatment of life-threatening infectious diseases such as hepatitis B, Gilead strives to advance patient care by supporting and fostering strong relationships with patients, physicians and care-givers.